Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 8/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 8/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.40 |
| ▸ | PYGM | P11217 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487347 | 0.90 | HSPB1 (0.41) | HSPB1MAPTPYGLMEN1KMT2A | |
| SCHEMBL3487130 | 0.87 | SMN1; SMN2 (0.43) | MAPTLPAR1LPAR5MEN1KMT2A | |
| SCHEMBL3487125 | 0.87 | SMN1; SMN2 (0.43) | MAPTLPAR1LPAR5MEN1KMT2A | |
| SCHEMBL3487711 | 0.86 | KDM4E (0.42) | HSPB1PYGLMEN1KMT2ARAB9A | |
| SCHEMBL3487980 | 0.86 | RAB9A (0.41) | MAPTMEN1KMT2ARAB9A | |
| SCHEMBL3487143 | 0.86 | L3MBTL1 (0.42) | MAPTPYGLMEN1KMT2A | |
| SCHEMBL3487913 | 0.85 | HSPB1 (0.47) | HSPB1MAPTMEN1KMT2A | |
| SCHEMBL3487485 | 0.85 | HSPB1 (0.43) | HSPB1MAPTPYGLMEN1KMT2A | |
| SCHEMBL3489428 | 0.84 | SOS1 (0.39) | MAPTMEN1KMT2ARAB9A | |
| SCHEMBL3488707 | 0.84 | HSPB1 (0.43) | HSPB1MAPTPYGLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138484-B1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2138484-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | HSPB1 3284/4885PIN1 3362/4885MAPT 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.